SCHEMBL19664922

SCHEMBL19664922

c1ccc(-c2cccc(P(c3ccccc3)c3ccccc3)c2-c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
CYP3A4 P08684 1/20 0.42
DRD1 P21728 2/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
HNF4A P41235 1/20 0.36
ALDH1A1 P00352 4/20 0.35
HSD17B10 Q99714 2/20 0.35
HPGD P15428 1/20 0.35
BCL2L1 Q07817 1/20 0.35
CYP2A6 P11509 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ESR1 P03372 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19305535 0.98 TDP1 (0.41) TDP1CYP3A4DRD1LMNAMAPT
SCHEMBL1768199 0.90 TDP1 (0.41) TDP1CYP3A4DRD1HNF4AALDH1A1
SCHEMBL28152682 0.88 TDP1 (0.42) TDP1CYP3A4DRD1HNF4AALDH1A1
SCHEMBL10700827 0.87 CYP3A4 (0.50) TDP1CYP3A4DRD1LMNAMAPT
SCHEMBL29929007 0.84 TDP1 (0.42) TDP1CYP3A4DRD1LMNAMAPT
SCHEMBL7795655 0.84 HDAC4 (0.43) ALDH1A1HSD17B10KDM4EHDAC4HDAC2
SCHEMBL4004840 0.83 TDP1 (0.50) TDP1CYP3A4DRD1ALDH1A1HSD17B10
SCHEMBL29635182 0.83 TDP1 (0.50) TDP1CYP3A4DRD1ALDH1A1HSD17B10
SCHEMBL7795653 0.83 MAPT (0.43) TDP1CYP3A4LMNAMAPTHTT
SCHEMBL31158582 0.83 MAPT (0.43) TDP1CYP3A4LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 TDP1 2819/4885CYP3A4 844/4885DRD1 1845/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 TDP1 2819/4885CYP3A4 844/4885DRD1 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.